Abstract | OBJECTIVE: DESIGN: Retrospective, noncomparative case series. PARTICIPANTS: METHODS: MAIN OUTCOME MEASURES: RESULTS: No patients had recurrences while on therapy. No further visual loss was encountered after starting the therapy. Six of the patients regained vision. All but two patients achieved prolonged drug-free remissions, ranging in duration between 15 and 96 months (median, 78 months). Side effects included transient bone marrow suppression, nausea, and fatigue. Secondary malignancy was encountered in one patient, whose carcinoma of the urinary bladder was treated successfully. CONCLUSIONS:
|
Authors | Esen Karamursel Akpek, Douglas A Jabs, Howard H Tessler, Brian C Joondeph, C Stephen Foster |
Journal | Ophthalmology
(Ophthalmology)
Vol. 109
Issue 8
Pg. 1506-13
(Aug 2002)
ISSN: 0161-6420 [Print] United States |
PMID | 12153803
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Antineoplastic Agents, Alkylating
- Immunosuppressive Agents
- Chlorambucil
- Cyclophosphamide
|
Topics |
- Adult
- Aged
- Antineoplastic Agents, Alkylating
(therapeutic use)
- Chlorambucil
(therapeutic use)
- Choroiditis
(diagnosis, drug therapy)
- Cyclophosphamide
- Disease Progression
- Female
- Fluorescein Angiography
- Follow-Up Studies
- Humans
- Immunosuppressive Agents
(therapeutic use)
- Male
- Middle Aged
- Retrospective Studies
- Treatment Outcome
- Visual Acuity
|